Boletín
HTA Quarterly Spring 2026
In this edition, we discuss the risks of relying on immature data for survival projections in oncology and the importance of selecting robust models to guide HTA decisions. We also explore key challenges and developments in HTA within the UK and Germany, including the impact of limited clinical evidence on NICE appraisals, with strategies to improve submission outcomes, and recent updates to Germany’s AMNOG dossier requirements, highlighting the evolution to trend-based estimates to better align benefit assessments with statutory health insurance patient populations.
Heard on the street
“The HTACG estimates that it will initiate around 50 joint clinical assessments (JCAs) of medicines… and for the first time, JCAs of selected high-risk medical devices.”
— EU’s Member State Coordination Group on Health Technology Assessment (HTACG) outlining key strategic priorities for 2026
Source: Health Technology Assessment – 2026 Work Programme adopted
Source: Health Technology Assessment – 2026 Work Programme adopted
HTA by the numbers
200%
The new HTACG target of 50 JCAs in 2026 is twice the target number of JCAs for 2025.
Sources:
Health Technology Assessment – 2026 Work Programme adopted
New EU rules for health technology assessments become effective | European Medicines Agency (EMA)
Sources:
Health Technology Assessment – 2026 Work Programme adopted
New EU rules for health technology assessments become effective | European Medicines Agency (EMA)
Conecte con nuestro equipo
Nuestro equipo de expertos líderes en valor se dedica a transformar las pruebas, los conocimientos sobre políticas y la inteligencia de mercado en estrategias efectivas de acceso al mercado global. Permítanos ayudarle a navegar con confianza por el complejo panorama de la atención sanitaria actual. Póngase en contacto con nosotros para descubrir cómo podemos ayudarle en sus objetivos.
